Tenax Therapeutics
Tenax Therapeutics is focused on developing therapies for pulmonary hypertension, specifically PH-HFpEF, a debilitating and often fatal disease with no current approved treatments. Their mission is to address the staggering unmet medical need in this area by leveraging clinical insights and innovative drug development strategies. Their lead drug candidate, TNX-103, is an oral formulation of levosimendan, which has a well-established safety profile and potential to lower pulmonary pressures by targeting splanchnic circulation. The company is conducting Phase 3 clinical trials and is guided by a team of heart failure and lung disease experts.
Industries
Nr. of Employees
small (1-50)
Tenax Therapeutics
Chapel Hill, North Carolina, United States, North America
Products
Oral formulation of a K-ATP channel activator and calcium sensitizer for PH-HFpEF (clinical candidate)
An oral therapeutic candidate developed to induce splanchnic venodilation and reduce venous blood volume, with the goal of lowering pulmonary capillary wedge pressure and improving exercise capacity in patients with pulmonary hypertension from HFpEF. Development leverages prior intravenous clinical safety and hemodynamic data.
Oral formulation of a K-ATP channel activator and calcium sensitizer for PH-HFpEF (clinical candidate)
An oral therapeutic candidate developed to induce splanchnic venodilation and reduce venous blood volume, with the goal of lowering pulmonary capillary wedge pressure and improving exercise capacity in patients with pulmonary hypertension from HFpEF. Development leverages prior intravenous clinical safety and hemodynamic data.
Services
Sponsor-led Phase 3 clinical development for PH-HFpEF
Sponsorship and operational leadership of registrational Phase 3 studies evaluating an oral therapy for pulmonary hypertension due to HFpEF, including patient enrollment, trial oversight, and open-label extension planning.
Sponsor-led Phase 3 clinical development for PH-HFpEF
Sponsorship and operational leadership of registrational Phase 3 studies evaluating an oral therapy for pulmonary hypertension due to HFpEF, including patient enrollment, trial oversight, and open-label extension planning.
Expertise Areas
- Clinical trial management
- Translational cardiopulmonary pharmacology
- Oral formulation development
- Regulatory strategy and submissions
Key Technologies
- ATP-sensitive potassium (K-ATP) channel modulation
- Calcium sensitization pharmacology
- Oral small-molecule formulation
- Invasive hemodynamic monitoring (right-heart catheterization, PCWP)